Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

Bilal Chughtai; Dean S Elterman; Richard Lee; Alexis E Te; Steven A Kaplan

doi:10.1177/1756287212457115

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia

Ther Adv Urol. 2012 Oct;4(5):267-72. doi: 10.1177/1756287212457115.

Authors

Bilal Chughtai¹, Dean S Elterman, Richard Lee, Alexis E Te, Steven A Kaplan

Affiliation

¹ James Buchanan Brady Department of Urology, Weill Cornell Medical College of Cornell University, New York, USA.

Abstract

Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) commonly affect older men. These bothersome symptoms can lead to a decreased quality of life. Currently, two classes of drugs - α-adrenergic blockers and 5α-reductase inhibitors - are prescribed to treat LUTS secondary to BPH. Due to their different mechanisms of action, these medications work in a synergistic manner. Trials of combination therapy have been conducted to assess its effect compared with monotherapy. Current data support combination therapy in men with moderately enlarged prostates and moderate to severe symptoms.

Keywords: 5α reductase inhibitor; CombAT trial; benign prostatic hyperplasia; combination therapy benign prostatic hyperplasia; dutasteride; fixed-dose benign prostatic hyperplasia; lower urinary tract symptoms; tamsulosin; α-adrenergic blocker.